KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $428.0 million.

  • Teva Pharmaceutical Industries' Net Income towards Common Stockholders rose 160.11% to $428.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $633.0 million, marking a year-over-year increase of 116.01%. This contributed to the annual value of -$2.0 billion for FY2024, which is 59.01% down from last year.
  • As of Q3 2025, Teva Pharmaceutical Industries' Net Income towards Common Stockholders stood at $428.0 million, which was up 56.20% from $274.0 million recorded in Q2 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Net Income towards Common Stockholders peaked at $428.0 million during Q3 2025, and registered a low of -$2.4 billion during Q4 2023.
  • In the last 3 years, Teva Pharmaceutical Industries' Net Income towards Common Stockholders had a median value of -$506.0 million in 2023 and averaged -$581.3 million.
  • In the last 5 years, Teva Pharmaceutical Industries' Net Income towards Common Stockholders crashed by 1,394.20% in 2021 and then soared by 160.11% in 2025.
  • Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' Net Income towards Common Stockholders stood at -$1.1 billion in 2021, then tumbled by 90.51% to -$2.1 billion in 2022, then decreased by 13.53% to -$2.4 billion in 2023, then soared by 88.33% to -$282.0 million in 2024, then spiked by 160.11% to $428.0 million in 2025.
  • Its last three reported values are $428.0 million in Q3 2025, $274.0 million for Q2 2025, and $213.0 million during Q1 2025.